Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients with Hypertrophic Cardiomyopathy – A Systematic Review and Meta-Analysis

Fatema Tashrifwala¹, Manisha Purushotham, Sai Krishna Bhushan

Clinical Research Intern, Stamford Hospital, Connecticut, US

Email address: 
flashrifw@stamhealth.org (Fatema Tashrifwala)

¹Corresponding author

To cite this article:

Received: February 8, 2023; Accepted: February 25, 2023; Published: May 29, 2023

Abstract: In this study, we aimed to meta-analyze all available data to provide a holistic, well-powered assessment of the effect of PIMSRA on LVOT gradient, LVEF, and anterior and posterior IVS thickness. PubMed, Cochrane Central, Embase, and Scopus were systematically searched from inception till October 2022 for published clinical trials assessing the efficacy of PIMSRA in patients with HCM using the keywords “PIMSRA” OR “Percutaneous Intramyocardial Septal Radiofrequency Ablation” OR “Liwen procedure. All five studies reported a change in LVOT gradient from the baseline. Integrated analysis showed no significant change from baseline (MD: -69.506; 95% CI: -77.047, -61.966; P = 0.089) (I² = 50.4%). Subgroup analyses based on follow-up revealed that there was no significant difference noted at 6 months according to data from 2 studies (MD: -65.351; 95% CI; -85.253, -45.450; P = 0.181) (I²= 44.1%) however data from 3 studies at one year follow up did reveal a significant difference from baseline (MD: -71.010; 95% CI: -80.262, -61.758; P = 0.047) (I² = 67.2%). Only three studies reported changes in LVEF from the baseline. This single-arm meta-analysis of 284 patients gathered from 5 clinical trials suggested that overall, after PIMSRA, LVOT gradient was reduced, and LVEF was slightly decreased. Additionally, no significant changes were observed in the anterior and posterior IVS thicknesses.

Keywords: HCM, PIMSRA, LVOT, LVEF, Anterior IVS Thickness, Posterior IVS Thickness, Efficacy

1. Introduction

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant intrinsic disease of the myocardium characterized by asymmetric hypertrophy and stiffness of the left ventricle along with the systolic anterior motion of the mitral valve, leading to a left ventricular outflow tract (LVOT) obstruction. It affects one in five hundred people worldwide and is the most common genetic heart disease in the US [1, 10]. The reduced volume of the heart chambers with a reduced capacity of the heart to pump blood results in a decreased stroke volume. LVOT obstruction is present at rest in about one-third of the patients. The symptoms include exertional dyspnea, exercise intolerance, orthopnea, peripheral edema, and syncope [2, 11]. Diagnostic modalities include echocardiography, electrocardiogram (ECG), and cardiovascular magnetic resonance imaging (CMRI). Identification of the HCM phenotype can be made by family screening and genetic testing in affected individuals [3, 4, 12]. The treatment goals are to reduce the severity of symptoms and prevent sudden cardiac death, particularly in young adults. Pharmacological treatment revolves around β-blockers or non-dihydropyridine calcium-channel blockers with the newer generation of drugs, including Mavacamten, Perhexiline, and Trimetazidine. Evaluation and follow-up are done by LVOT gradient, left ventricular ejection fraction (LVEF), and myocardial hypertrophy measured by Interventricular septum (IVS) thickness [5]. In patients who are refractory to maximum dosage (about 40%) or have an intolerance to drugs, surgical options like septal myectomy and transcatheter mitral valve repair may be considered. The downside to these is the need for a sternotomy. Minimally
invasive procedures which can instead be done are high-intensity focused ultrasonography and radiofrequency ablation, or Alcohol septal ablation (ASA), which come with their own risk of complications with chances of occurrence ranging from 0.5-5% [6]. The suitability of ASA is limited by septal coronary anatomy and the risk of alcohol being injected into the wrong site. Advancements in techniques have now led to the use of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) as a promising technique for such patients. This technique uses a radiofrequency electrode needle inserted under guidance into the hypertrophied IVS to achieve ablation [4, 7]. Trials have shown reductions in IVS thickness and LVOT gradients along with improvement in New York Heart Association (NYHA) functional classification following PIMSRA, but these studies have been limited by small sample sizes, thus being underpowered to reliably demonstrate any significant differences in outcomes. In this study, we aimed to meta-analyze all available data to provide a holistic, well-powered assessment of the effect of PIMSRA on LVOT gradient, LVEF, and anterior and posterior IVS thickness.

2. Methods

PubMed, Cochrane Central, Embase, and Scopus were systematically searched from inception till October 2022 for published clinical trials assessing the efficacy of PIMSRA in patients with HCM using the keywords “PIMSRA” OR “Percutaneous Intramyocardial Septal Radiofrequency Ablation” OR “Liwen procedure.” Studies that reported change in either LVOT gradient, IVS thickness, or LVEF were selected. No time or language restrictions were applied. All case reports were excluded, and only clinical trials were included. The search and data extraction were conducted independently by two reviewers (MP, FT). A third reviewer (IH) was consulted to resolve discrepancies. All statistical analyses were conducted on Open Meta-analyst. Trials were pooled using a continuous random effects model (DL: DerSimonian-Laird), and results were presented with 95% confidence intervals (CIs). P value <0.05 was considered significant. Subgroup analysis according to time at follow-up was done. Heterogeneity was evaluated using Higgins I², with I² > 75% regarded as substantial heterogeneity.

3. Contents and Results

The initial search yielded 72 potential studies. After exclusions, 5 trials remained for analysis [1, 3, 4, 7, 8, 9]. The detailed literature search is highlighted in the PRISMA Flow Chart (Supplementary Material Figure 1). The characteristics of the included studies have been summarized in Table 1.

All five studies reported a change in LVOT gradient from the baseline (Figure 1A). Integrated analysis showed no significant change from baseline (MD: -65.351; 95% CI: -85.253, -45.450; P = 0.181) (I² = 44.1%) however data from 3 studies at one year follow up did reveal a significant difference from baseline (MD: -71.010; 95% CI: -80.262, -61.758; P = 0.047) (I² = 67.2%).

Only three studies reported changes in LVEF from the baseline (Figure 1B). Integrated analysis Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation showed a significant change from baseline at one-year follow-up in patients who underwent PIMSRA (MD: -1.760; 95% CI: -3.239, -0.282; P = 0.047) (I² = 67.2%).

The pooled analysis from four studies that reported anterior IVS thickness showed no significant change from baseline (MD: -9.707; 95% CI: -10.819, -8.595; P = 0.095) (I² = 52.9%). Subgroup analyses based on follow-up revealed that there was a significant difference noted at 6 months (MD: -11.285; 95% CI: -12.825, -9.744; P = 0.933) (I² = 0%) or at one-year follow-up (MD: -9.147; 95% CI: -9.837, -8.456; P = 0.650) (I² = 0%) (Figure 1C).

The combined analysis of the four included studies reporting posterior IVS thickness showed no significant change from baseline (MD: -8.859; 95% CI: -10.073, -7.644; P = 0.119) (I² = 48.7%). Additionally, there was no significant difference noted in the subgroup analysis at 6 months (MD: -10.278; 95% CI: -12.133, -8.423; P = 0.934) (I² = 0%) and at one-year follow-up (MD: -8.335; 95% CI: -9.880, -6.789; P = 0.072) (I² = 69.14%) (Figure 1D).

4. Discussion

Our meta-analysis had some limitations. The number of studies and the sample size available for analysis were limited, and most patients were of Chinese origin. Furthermore, no studies have evaluated the long-term effects on cardiac conduction due to the scar tissue formed following ablation. Therefore, further studies with long-term follow-up having large sample sizes from different patient populations and ethnicities should be done to demonstrate the effectiveness of PIMSRA with more statistical power. Outcomes measuring procedure safety, such as intraoperative and postoperative complications, should also be recorded and compared with a control group.

5. Conclusion

This single-arm meta-analysis of 284 patients gathered from 5 clinical trials suggested that overall, after PIMSRA, LVOT gradient was reduced, and LVEF was slightly decreased. Additionally, no significant changes were observed in the anterior and posterior IVS thicknesses. Our results had substantial heterogeneity, which could be explained due to differences in the follow-up periods and studies with small sample sizes. It is important to note that even though no significant difference in follow-up was seen from the baseline at 6 months, there was indeed a significant difference noted at one year when assessing the outcomes of the LVOT gradient.
This could suggest that longer follow-up periods are imperative to truly observe the procedure's efficacy.

Figure 1. Forrest plots show the results of the analysis.
Table 1. Characteristics of included studies.

<table>
<thead>
<tr>
<th>Included Studies</th>
<th>Year</th>
<th>Characteristics of Patients</th>
<th>Number of participants</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou M [1]</td>
<td>2022</td>
<td>Age in years: 33 - 61 Gender: M - 125 F - 75 NYHA Class: M - 125 Class III/IV</td>
<td>200</td>
<td>1 year</td>
</tr>
<tr>
<td>Qian D [3]</td>
<td>2021</td>
<td>Age in years: 15 - 79 Gender: M - 20 F - 10 F - 2 NYHA Class: Chest pain, syncope, NYHA Class III/IV LVOT Gradient: &gt;50 mmHg IVS Thickness: 15-25 mm</td>
<td>30</td>
<td>1 year</td>
</tr>
<tr>
<td>Zuo L [7]</td>
<td>2020</td>
<td>Age in years: 15 - 25 Gender: M - 20 F - 10 M - 13 F - 2 NYHA Class: Chest pain, syncope, NYHA Class III/IV LVOT Gradient: &gt;50 mmHg IVS Thickness: &gt; 50 mmHg</td>
<td>15</td>
<td>6 months</td>
</tr>
<tr>
<td>Liu L [6]</td>
<td>2018</td>
<td>Age in years: 24 - 57 Gender: M - 15 F - 2 NYHA Class: Chest pain, syncope, NYHA Class III/IV LVOT Gradient: &gt;50 mmHg IVS Thickness: 15-25 mm</td>
<td>9</td>
<td>6 months</td>
</tr>
<tr>
<td>Liu LW [8]</td>
<td>2019</td>
<td>Two NYHA class II &amp; Seven NYHA class III cases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NYHA: New York Heart Association; LVOT: Left Ventricular Outflow Tract; IVS: Interventricular Septum

Abbreviations

HCM: Hypertrophic Cardiomyopathy
LVOT: Left ventricular Outflow Tract
US: United States
CMRI: Cardiovascular Magnetic Resonance Imaging
LVEF: Left Ventricular Ejection Fraction
ASA: Alcohol Septal Ablation
PIMSRA: Percutaneous Intramyocardial Septal Radiofrequency Ablation
IVS: Interventricular Septum
NYHA: New York Heart Association
CI: Confidence Interval
MD: Mean Deviation

Author Declarations

Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Conflict of Interest
The authors have no relevant financial or non-financial interests to disclose.

Author Contribution
All authors had access to the data and a role in writing the manuscript. All authors have reviewed the manuscript and approved it in its current form.

Code Availability
Following PRISMA guidelines. Software used was Open Meta analyst.

Availability of Data and Material
Transparent.

Ethics Approval
This is a review article (metanalysis). According to PRISMA no ethical approval is required.

Consent to Participate
N/A

Consent to Publish
N/A

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

References


Mosterd A, Hoes AW. Clinical epidemiology of heart failure.


